OKYO Pharma LTD to Ring Nasdaq Opening Bell

OKYO Pharma LTD announced that its Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Nasdaq Opening Bell on December 19, 2025. This event commemorates the company's advancements in innovative treatments, particularly its lead candidate, urcosimod. Urcosimod is a novel therapy targeting neuropathic corneal pain (NCP), a condition with no currently FDA-approved treatments. The company's approach involves a lipid-conjugated chemerin peptide agonist aimed at addressing a significant unmet medical need. OKYO Pharma has reported positive Phase 2 results for urcosimod in treating NCP, demonstrating favorable outcomes in corneal nerve health and pain reduction. The company is planning a larger, multicenter trial for urcosimod in NCP patients, scheduled to commence in Q1 2026. The announcement was made via Form 6-K, including an exhibit detailing the news and providing background information on NCP and urcosimod.